Ticker League

EBITDA for Bristol-Myers Squibb (BMY) 1987-2026

Latest filings through · Reported

Metric

TTM

$13.7B

YoY change

+359.1%

5Y CAGR

+24.2%

Peak year (FY2021)

$20.1B

EBITDA history chart for Bristol-Myers Squibb (BMY) from 2016 to 2025

Latest: $14.5B

EBITDA growth chart for Bristol-Myers Squibb (BMY) from 2016 to 2025

Latest: +359.1%

EBITDA history table for Bristol-Myers Squibb (BMY) from 1987 to 2025

  • FY2025$14.5B+359.1%
  • FY2024$3.17B-83.6%
  • FY2023$19.4B+0.8%
  • FY2022$19.2B-4.5%
  • FY2021$20.1B+308.2%
  • FY2020$4.93B-33.2%
  • FY2019$7.38B+8.7%
  • FY2018$6.79B+11.0%
  • FY2017$6.12B-5.4%
  • FY2016$6.46B+145.1%
  • FY2015$2.64B-13.6%
  • FY2014$3.05B-20.8%
  • FY2013$3.85B+20.3%
  • FY2012$3.2B-58.7%
  • FY2011$7.75B+13.6%
  • FY2010$6.82B+5.1%
  • FY2009$6.49B+10.0%
  • FY2008$5.9B+33.5%
  • FY2007$4.42B+33.4%
  • FY2006$3.31B-29.0%
  • FY2005$4.67B-13.2%
  • FY2004$5.37B-6.1%
  • FY2003$5.72B+18.3%
  • FY2002$4.84B-17.8%
  • FY2001$5.89B-12.6%
  • FY2000$6.73B+13.8%
  • FY1999$5.92B+16.5%
  • FY1998$5.08B+1.0%
  • FY1997$5.03B+12.5%
  • FY1996$4.47B+10.1%
  • FY1995$4.06B+14.5%
  • FY1994$3.55B+30.9%
  • FY1993$2.71B+20.2%
  • FY1992$2.26B-25.1%
  • FY1991$3.01B+14.4%
  • FY1990$2.63B+105.9%
  • FY1989$1.28B-34.6%
  • FY1988$1.96B+20.1%
  • FY1987$1.63B—

EBITDA values are taken from Bristol-Myers Squibb's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA at Bristol-Myers Squibb (BMY)

According to Bristol-Myers Squibb's latest reported financial statements, the company's current EBITDA (TTM) is $13.7B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

Bristol-Myers Squibb (BMY) most recent annual EBITDA stands at $14.5B (2025) – surged 359.1% year-over-year.

Bristol-Myers Squibb EBITDA has grown on net over the period, with a +24.2% compound annual growth rate over 2020–2025 (5 years).

Between 2021 and 2025, Bristol-Myers Squibb EBITDA declined 27.7%, falling from $20.1B to $14.5B.

The highest annual EBITDA of $20.1B was reported in 2021. The lowest in the available history was $1.28B in 1989.

Bristol-Myers Squibb EBITDA by Year

Bristol-Myers Squibb EBITDA 2025: $14.5B

Bristol-Myers Squibb EBITDA in 2025 was $14.5B, surged 359.1% from 2024.

Bristol-Myers Squibb EBITDA 2024: $3.17B

2024's EBITDA for Bristol-Myers Squibb came in at $3.17B, plunged 83.6% below 2023.

Bristol-Myers Squibb EBITDA 2023: $19.4B

Bristol-Myers Squibb posted EBITDA of $19.4B in 2023, edged up 0.8% from 2022.

Bristol-Myers Squibb EBITDA 2022: $19.2B

In 2022, Bristol-Myers Squibb reported EBITDA of $19.2B, edged down 4.5% below 2021.

Bristol-Myers Squibb EBITDA 2021: $20.1B

Bristol-Myers Squibb EBITDA in 2021 was $20.1B.

See more financial history for Bristol-Myers Squibb (BMY).

Sector peers by EBITDA

Healthcare peers of Bristol-Myers Squibb (BMY), ranked by their latest EBITDA

Frequently asked questions

Trains Profitability

Bristol-Myers Squibb (BMY) Key Financials

Charts, filings, and peer comparison for every metric

Operations

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview
Capital Return

How this company returns cash to shareholders — buybacks, dividends, and stock splits.